Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson has extensive experience in the development of FDA- and EMA-approved orphan products and has held global leadership roles across multiple disciplines of the life sciences industry, including clinical development, regulatory, and medical affairs.Dr. van Es-Johansson, an expert in orphan drug development, is currently the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance. For more than a decade prior to that, Dr. van Es-Johansson was at Sobi, an international rare disease company headquartered in Stockholm, Sweden. During her tenure at Sobi, she held a range of executive roles of incre
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.MarketBeat
- Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 [Yahoo! Finance]Yahoo! Finance
- Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024Business Wire
- Savara Announces New Employment Inducement GrantBusiness Wire
- Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
SVRA
Earnings
- 11/9/23 - Miss
SVRA
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- SVRA's page on the SEC website